The Week in Review: Nov 30 – Dec 7, 2018

Friday, Dec 7, 2018 News Recap: Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF A low dose of tenofovir disoproxil fumarate (TDF) may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease, according to new research. Join Us to Honour & Remember Our Friend Phil Wilkin On Friday December 14,...

Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF

A low dose of tenofovir disoproxil fumarate (TDF) may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease, according to new research. TDF (Viread, Gilead) is currently approved for the treatment of chronic hepatitis B virus infection in adults and pediatric patients who are 12 years and older. Although the treatment is effective in inhibiting hepatitis

Switching to Tenofovir vs Continuing Entecavir in Chronic Hepatitis B

Switching to tenofovir disoproxil fumarate (TDF) is more efficacious than continuing entecavir (ETV) for achieving an optimal response in patients with chronic hepatitis B with a partial virologic response to ETV, according to a multicenter, open-label, randomized controlled study published in the Journal of Viral Hepatitis. No studies have directly compared the efficacy of switching from ETV to TDF with that of continuing ETV; therefore, researchers pros

The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

BRIEF: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B

IN BRIEF: RECOMMENDATION The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF). Read more: https://www.cadth.ca/tenofovir-alafenamide  

The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Tenofovir disoproxil fumarate (TDF) not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives

Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen — administration of hepatitis B vaccine and prote